Lipella Pharmaceuticals' LP-10 shows promise as a targeted treatment for OLP, offering safety and efficacy in recent trials, according to Michael Chancellor, MD.
Michael Chancellor, MD
Advertisement
Michael Chancellor, MD, is the Chief Medical Officer of Lipella Pharmaceuticals.
Articles by Michael Chancellor, MD
Advertisement
Latest Updated Articles
How LP-10 Could Transform Treatment for Oral Lichen PlanusPublished: October 7th 2025 | Updated:
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Reviewing Type 2 Inflammation Through a Different Lens
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5
